Yeah, same @Deebo.
Jakjazz, I think the fancy answer to this is that in evolutionary terms, canines are quite a lot closer to humans than rodents, and therefore their biological systems - including their mTOR signalling system- is more similar to our own, and this is why PAA chose to develop the mpl tablet for canines first and use that tablet then in human trials - so this is why they decided to give the MND trial a dual use as an MND trial and also a tolerability and pharmocokinetic trial for human cancer, and other uses. . In fact in cancer research, this has been the trend in recent years, going from lab rodent to canine to human. Cheers
PAA 2022 , Human Trials , Covid , MND , Oncology , HVTL-1, K9 Phase III, page-1427
-
- There are more pages in this discussion • 40 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $100.1M | |||
| Open | High | Low | Value | Volume |
| 22.5¢ | 22.5¢ | 22.5¢ | $9.238K | 41.05K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 78996 | 22.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.5¢ | 124981 | 4 |
View Market Depth
| Last trade - 10.06am 17/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |